
Ronald Booth
Clinical Biochemist and Full Professor at the University of Ottawa, directing the Immunology and Neurobiomarkers Section of the EORLA regional laboratory at The Ottawa Hospital.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
Sep 2, 2026
Moving Science: The impact of Neurofilament light on MS Care
16:27
16:41
16:49
17:09
29:42

Simon ThebaultHOST
about how we can use this test both as a one-off measurement and how we need to consider it in the context of other physiological covariates, if you like, as opposed to how we monitor it over time.

Ronald BoothGUEST
Yeah, so that's, I think it's a really important point to the difference between an individual measurement and trending over time.

Ronald BoothGUEST
And as a laboratory, maybe I'll back up just one quick step in terms of when a physician or a patient gets a result, the lab generally flags it as abnormal or normal.

Ronald BoothGUEST
We spend a lot of time in the lab trying to pick these cutoffs and identify what's normal, what's abnormal.
12 MINS LATER

Simon ThebaultHOST
If this is how neurofilament is being used, how specific is NFL in this context for this particular problem of identifying eurilapse biology? Are there any problems in using the test in this way?